表紙
市場調查報告書
商品編碼
958562

類風濕性關節炎診斷檢驗的全球市場

Rheumatoid Arthritis Diagnosis Tests

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 299 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球類風濕性關節炎診斷檢驗的市場規模在分析期間(2020年∼2027年)內預計將以5.2%的年複合成長率增長,從2020年的5億9,990萬美元到2027年達到8億5,280萬美元。本報告分析市場區隔之一的血清檢驗部門在分析期間結束前預測將以5.5%的年率增長,達到6億3,020萬美元。

本報告提供全球類風濕性關節炎診斷檢驗市場的相關調查,提供市場佔有率,趨勢和預測,成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Abbott Laboratories
  • Antibodies Inc.
  • Aviva Systems Biology Corporation
  • Beckman Coulter, Inc.
  • Bio-Rad laboratories Inc.
  • Euro Diagnostica AB
  • F. Hoffmann-La Roche AG
  • Qiagen NV
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

目錄

I. 簡介,調查手法,調查範圍

II. 摘要整理

  • 市場概要
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • Covid-19的影響和即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與成長要素
  • 全球市場預測

III. 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 中南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 簡介公司總數:42公司
目錄
Product Code: MCP14459

Global Rheumatoid Arthritis Diagnosis Tests Market to Reach $766.7 Million by 2026

Rheumatoid Arthritis (RA), a chronic autoimmune disease, causes inflammation in the joints, muscles, connective tissues, fibrous tissues, and tendons causing pain and swelling. The disease is developed when certain cells of the immune system do not work properly and attach the healthy joints. The disease mostly affects the wrists, hands, and feet. In this condition, the body identifies the body tissues as antigens and produces antibodies against them resulting in inflammation. Major symptoms of the disease include swelling, pain, joint stiffness, joint deformity, fever, weight loss, loss of mobility and function, unsteadiness while walking, and weakness. Different types of rheumatoid arthritis are seronegative, seropositive and juvenile idiopathic arthritis. Women are more prone to the disease compared to men and it is common among the age group 40 to 60. The diagnosis of the disease depends on the symptoms, physical examination, x-ray, scan, and blood test results of a patient.

Though the disease can attack at any age its prevalence generally begins in people between 30 to 60 years of age. Females are more two to three times more prone to RA than men. The US had the lowest rate of RA prevalence in the recent past in comparison to the other eight major markets like Australia, the US, Japan, France Italy, Germany, Spain and the UK. The US had an RA prevalence rate of 67% in comparison with the standard 73% rate in the other eight markets. The UK demonstrated the highest prevalence of RA at 84%. Alterations in the population of the U.S are expected to bring an unprecedented increase in the growth of incidence cases of RA in the U.S. till 2027. Physicians in the U.S. are expected to focus heavily on diagnostic processes for RA. Rheumatoid arthritis is better managed when detected early as the inflammation reduction process can be begun early. The clinical demonstration of RA is swelling and redness of joints, pain, swelling and stiffness. Diagnosing the disease involves a physical examination, an array of imaging tests, blood tests and medical history analysis of patients and patient`s families. The diagnosis of RA can be influenced by the challenge of separating the disease from other autoimmune disorders showing similar symptoms. A combination of diagnostic processes including a thorough symptomatic evaluation of the patient, X-ray analysis, blood tests and scans and physical examinations are recommended for the optimal management of this disease.

Amid the COVID-19 crisis, the global market for Rheumatoid Arthritis Diagnosis Tests estimated at US$579.8 Million in the year 2020, is projected to reach a revised size of US$766.7 Million by 2026, growing at a CAGR of 4.8% over the analysis period. Serology Tests, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$561.3 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Monitoring Ra Treatment Efficiency Tests segment is readjusted to a revised 4% CAGR for the next 7-year period. This segment currently accounts for a 31.6% share of the global Rheumatoid Arthritis Diagnosis Tests market.

The U.S. Market is Estimated at $124.3 Million in 2021, While China is Forecast to Reach $113.5 Million by 2026

The Rheumatoid Arthritis Diagnosis Tests market in the U.S. is estimated at US$124.3 Million in the year 2021. The country currently accounts for a 20.66% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$113.5 Million in the year 2026 trailing a CAGR of 6.1% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR while Rest of European market (as defined in the study) will reach US$120.4 Million by the close of the analysis period.

Global demographic trends spell opportunities for the rheumatoid arthritis (RA) diagnostic tests market. It is acknowledged that prevalence of RA increases with age, and therefore rising aging population widens the demand for diagnosis tests as well as treatments for RA. Over the course of the next two decades, the proportion of 65+ individuals in the total population is expected to double in countries such as the US, UK and Australia. As per the World Health Organization (WHO), total number of people aged 65-years and above is projected to grow from the existing 605 million to nearly 2 billion by the year 2050. While nearly 89 million people in the US are forecast to be 65-years or above by 2050, around 40% of citizens in Japan are projected to belong to the age group by 2060. While the increase in life expectancy represents one of the greatest achievements of the past century, it also poses a significant challenge for healthcare systems. People might live more years but the average number of healthy years is on a decline given the risk of contracting later life conditions such as dementia. About 55% of global healthcare expenditure is likely to be spent on chronic diseases including cardiovascular diseases, cancer and respiratory diseases.

With advancing age, the incidence of various health ailments increases, necessitating the need for laboratory tests for diagnosing the specific diseases such as RA. Impact of autoimmune diseases such as RA on quality of life and associated high cost of treatments are prompting governments and healthcare providers to encourage preventive care, especially with focus on aging population. The growing aging population is therefore offering continuous opportunities for the autoimmune disease diagnostics market, as with advancing age the incidence of various autoimmune conditions such as RA increases, which results in rise in testing volumes translating to higher demand for testing techniques for RA. As RA is mostly common among the old people, and the geriatric population has been increasing recently, the opportunities in the global rheumatoid arthritis diagnosis test market are expected to be on the rise in the future.

Select Competitors (Total 65 Featured) -

  • Abbott Laboratories
  • Antibodies Inc.
  • Aviva Systems Biology Corporation
  • Beckman Coulter, Inc.
  • Bio-Rad laboratories Inc.
  • Euro Diagnostica AB
  • F. Hoffmann-La Roche AG
  • Qiagen NV
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Rheumatoid Arthritis
    • Causes and Risk Factors
    • Symptoms
    • Rheumatoid Arthritis Diagnostic Tests
    • Serological Tests
    • Monitoring RA Treatment Efficiency Tests
    • Kidney Function Tests
    • Impact of Covid-19 and a Looming Global Recession
    • Impact of COVID-19 on Rheumatoid Arthritis Diagnostic Tests
    • Global Market Outlook and Prospects
    • Global Rheumatoid Arthritis Diagnostic Tests Market Set to Witness Significant Growth
    • Select RA Diagnostic Tests by Player
    • The US and Europe Dominate the Global Market, Developing Countries to Witness Fastest Growth
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Rheumatoid Arthritis Propels the Demand for Rheumatoid Arthritis Diagnosis
    • EXHIBIT 1: Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
    • Growing Aging Population to Drive the Demand for RA Diagnostic Tests
    • EXHIBIT 2: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Increasing Use of Rapid Diagnosis Tests Platform
    • Select List of RA Biomarkers used in Clinical Practice
    • Investigational Biomarkers to Diagnose and Monitor RA
    • New Biomarker Tests to Drive the Market Growth
    • More Specific Biomarker Tests
    • Growing Demand for Multiple Tests
    • Repercussions of Sub Optimal Accuracy in RA Testing Drive the Need for Multiple Tests
    • Recent Advancements in Treatment Methods to Boost Market Growth
    • Uptrend in Healthcare Expenditure Drives Opportunities
    • EXHIBIT 3: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Increase in Number of Hospitals & Diagnostics Centres Augurs Well for Market in Developing Regions
    • Increasing Obesity Levels Underpins Market Growth
    • Obesity Statistics
    • EXHIBIT 4: Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Technological Advancements Widen the Capabilities of RA Arthritis Tests
    • A Few of the Recent Launches and Advancements
    • Rapid RA Diagnostic Tests for Obtaining Results in Minutes
    • imaware™ Introduces At-Home Rheumatoid Arthritis Screening Test
    • Swedish Biotech Breaks Barrier to Diagnosis with Rheumatoid Arthritis Test
    • Scipher Medicine® Ties Up with Ambry Genetics® to Bring Precision Medicine Test for Rheumatoid Arthritis to Market
    • A New Blood Test Could to Predict Rheumatoid Arthritis
    • IPM Launches Innovative Program for Rheumatoid Arthritis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
    • TABLE 4: World Current & Future Analysis for Serology Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Serology Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Serology Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 7: World Current & Future Analysis for Monitoring RA Treatment Efficiency Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Monitoring RA Treatment Efficiency Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Monitoring RA Treatment Efficiency Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 10: World Current & Future Analysis for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 13: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
    • TABLE 16: World Current & Future Analysis for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Ambulatory Surgical Centers by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 19: USA Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 22: USA Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 28: Canada Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • JAPAN
    • TABLE 31: Japan Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 34: Japan Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • CHINA
    • TABLE 37: China Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 40: China Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: China Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: China 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • EUROPE
    • TABLE 43: Europe Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
    • TABLE 46: Europe Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 49: Europe Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • FRANCE
    • TABLE 52: France Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: France Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: France 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 55: France Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: France Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: France 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • GERMANY
    • TABLE 58: Germany Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Germany Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Germany 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 61: Germany Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Germany Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Germany 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • ITALY
    • TABLE 64: Italy Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Italy Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Italy 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 67: Italy Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Italy Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Italy 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • UNITED KINGDOM
    • TABLE 70: UK Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: UK Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: UK 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 73: UK Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: UK Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: UK 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • SPAIN
    • TABLE 76: Spain Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Spain Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Spain 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 79: Spain Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Spain Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Spain 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • RUSSIA
    • TABLE 82: Russia Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Russia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Russia 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 85: Russia Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Russia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Russia 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • REST OF EUROPE
    • TABLE 88: Rest of Europe Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of Europe 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 91: Rest of Europe Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Europe 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • ASIA-PACIFIC
    • TABLE 94: Asia-Pacific Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 95: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 96: Asia-Pacific 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
    • TABLE 97: Asia-Pacific Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 100: Asia-Pacific Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 102: Asia-Pacific 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • AUSTRALIA
    • TABLE 103: Australia Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Australia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 105: Australia 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 106: Australia Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Australia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 108: Australia 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • INDIA
    • TABLE 109: India Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: India Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 111: India 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 112: India Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 113: India Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 114: India 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • SOUTH KOREA
    • TABLE 115: South Korea Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: South Korea Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 117: South Korea 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 118: South Korea Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 119: South Korea Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 120: South Korea 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 121: Rest of Asia-Pacific Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 123: Rest of Asia-Pacific 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 124: Rest of Asia-Pacific Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 125: Rest of Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 126: Rest of Asia-Pacific 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • LATIN AMERICA
    • TABLE 127: Latin America Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 128: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 129: Latin America 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
    • TABLE 130: Latin America Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 132: Latin America 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 133: Latin America Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 135: Latin America 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • ARGENTINA
    • TABLE 136: Argentina Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 137: Argentina Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 138: Argentina 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 139: Argentina Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Argentina Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 141: Argentina 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • BRAZIL
    • TABLE 142: Brazil Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Brazil Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 144: Brazil 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 145: Brazil Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Brazil Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 147: Brazil 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • MEXICO
    • TABLE 148: Mexico Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Mexico Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 150: Mexico 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 151: Mexico Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Mexico Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 153: Mexico 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • REST OF LATIN AMERICA
    • TABLE 154: Rest of Latin America Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Rest of Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 156: Rest of Latin America 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 157: Rest of Latin America Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Rest of Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 159: Rest of Latin America 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • MIDDLE EAST
    • TABLE 160: Middle East Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 161: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 162: Middle East 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
    • TABLE 163: Middle East Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 165: Middle East 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 166: Middle East Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 168: Middle East 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • IRAN
    • TABLE 169: Iran Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Iran Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 171: Iran 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 172: Iran Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Iran Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 174: Iran 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • ISRAEL
    • TABLE 175: Israel Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Israel Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 177: Israel 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 178: Israel Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Israel Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 180: Israel 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • SAUDI ARABIA
    • TABLE 181: Saudi Arabia Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Saudi Arabia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 183: Saudi Arabia 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 184: Saudi Arabia Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Saudi Arabia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 186: Saudi Arabia 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 187: UAE Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: UAE Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 189: UAE 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 190: UAE Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 191: UAE Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 192: UAE 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • REST OF MIDDLE EAST
    • TABLE 193: Rest of Middle East Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Rest of Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 195: Rest of Middle East 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 196: Rest of Middle East Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 197: Rest of Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 198: Rest of Middle East 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027
  • AFRICA
    • TABLE 199: Africa Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Africa Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 201: Africa 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2012, 2021 & 2027
    • TABLE 202: Africa Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Africa Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 204: Africa 15-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories, Hospitals and Ambulatory Surgical Centers for the Years 2012, 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 65